Neurogene (NGNE)

• Market cap: $472M
• 1 day: -1.71%
• 5 days: 1.56%
• 1 month: 4.9%
• 3 months: 36.07%
• 6 months: 50.28%
• Year to date: 45.59%
• 1 year: 54.72%
• 5 years: -85.4%
• 10 years: -78.85%
• Sector: Healthcare
• Industry: Biotechnology

About: Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACT(Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.

Employees: 131